Skip to main content
. 2021 Feb 3;13(4):591. doi: 10.3390/cancers13040591

Figure 1.

Figure 1

Schematic representation of the suggested effect of immunoglobulin class M (IgM)-rheumatoid factor (RF) in limiting naïve and central memory T-cells recirculation in non-small lung cancer (NSCLC) patients, leading to an impaired CD137+ tumor-directed T-cells expansion and a consequent failure of immune-based immunotherapies.